GlassScriptPhysician profile
Timothy Gensler
NPI 1689668170
$3,813.36
in general payments reported to CMS, 2019-2025
17 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $381 · 2021: $369 · 2022: $491 · 2023: $1,572 · 2024: $166 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,300 · Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,300.00 |
| Food and Beverage | $756.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $1,300.00 | 2023 | |
| Abbvie INC. | $749.74 | 2019-2024 | |
| Glaxosmithkline, LLC. | $661.42 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $239.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $189.48 | 2019-2025 | |
| Pfizer INC. | $184.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $134.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $128.68 | 2021-2024 | Orencia |
| Amgen INC. | $51.91 | 2025 | Uplizna |
| Zimmer Biomet Holdings, INC. | $44.77 | 2019 | |
| Ani Pharmaceuticals, INC. | $23.66 | 2023 | Purified Cortrophin Gel |
| Ucb, INC. | $22.28 | 2025 | Bimzelx |
| Horizon Therapeutics Plc | $19.83 | 2021 | |
| Organon LLC | $18.26 | 2022 | |
| Antares Pharma, INC. | $16.06 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $15.20 | 2019 | |
| Genzyme Corporation | $13.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gensler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.